REPH


The FDA Turns Recro Pharma (REPH) Away, But This Analyst Remains Bullish

Recro Pharma (NASDAQ:REPH) received devastating news on Thursday. The U.

Recro Pharma (REPH) Stock’s Crashing; Here’s What Investors Need to Know

Recro Pharma (NASDAQ:REPH) announced today that its lead compound, IV Meloxicam, received a CRL from the FDA, which is a nice way of saying …

Stock Update (NASDAQ:REPH): Here’s Why Recro Pharma Inc Shares Jumped 22% Today

Recro Pharma Inc (NASDAQ:REPH) investors have a smile on their faces Monday evening, after the drug maker announced that they have entered into an …

Brean Capital Boosts Price Target on Recro Pharma Inc Following Investor Meetings

Brean Capital analyst Jonathan Aschoff came out with a favorable report on Recro Pharma Inc (NASDAQ:REPH) following several investor meetings with the company’s management. …

Brean Capital Maintains Buy Rating on Recro Pharma Inc Due to Acquisition of Manufacturing Facility and Meloxicam

Brean Capital’s analyst Jonathan Aschoff came out today with a research note on Recro Pharma Inc (NASDAQ:REPH), maintaining a price target of $26 …